Skip to Content

Moderna Inc MRNA

Rating as of

Morningstar’s Analysis

Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price


5-Star Price


Economic Moat


Capital Allocation


Raising Moderna's FVE to $182 on Pipeline Progress and Additional 2022 COVID-19 Vaccine Sales

Karen Andersen, CFA Sector Strategist

Analyst Note

| Karen Andersen, CFA |

We're raising our Moderna fair value estimate to $182 from $159 after adding a cardiology-focused mRNA treatment candidate and an Epstein-Barr prophylactic vaccine to our forecast, as well as incorporating recent COVID-19 vaccine contracts, including the recent U.K., Covax, and South Korea contracts. Overall, we still model $17.2 billion in COVID-19 vaccine sales in 2021 but have raised our forecast for 2022 to $19.7 billion (from $17.2 billion), incorporating recent contracts. These assumptions still fit with Moderna's updated guidance as of November 2021 of $15 billion-$18 billion in 2021 and $17 billion-$22 billion in 2022. In our model, we assume a significant drop in COVID-19 vaccine sales to $5 billion in 2023 as additional broad booster programs could be winding down, and $2 billion annually beginning in 2024 as the postpandemic focus could narrow to vulnerable populations (largely the elderly). In addition, we now include a 30% probability of approval and potential $2 billion in peak sales for AZN-8601, a VEGF-A therapy partnered with AstraZeneca that had positive phase 2 data in a handful of coronary artery bypass patients in November. We also include a 30% probability of approval for Moderna's Epstein-Barr vaccine, which has now entered phase 1 clinical trials. Despite Moderna's massive success with its COVID-19 vaccine, we think the changing competitive landscape, uncertain virus evolution, and many unknowns for safety and efficacy of its technology beyond COVID-19 all create too many questions to grant the firm an economic moat. Despite the recent pullback in share prices, we continue to see Moderna shares as slightly overvalued. 

Read Full Analysis

Company Profile

Business Description

Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its COVID-19 vaccine, which was authorized in the United States in December 2020. Moderna had 24 mRNA development programs as of early 2021, with 13 of these in clinical trials. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.

200 Technology Square
Cambridge, MA, 02139
T +1 617 714-6500
Sector Healthcare
Industry Biotechnology
Most Recent Earnings Sep 30, 2021
Fiscal Year End Dec 31, 2021
Stock Type Speculative Growth
Employees 1,300